Scientific Breakthrough in Predicting Binding Affinities

Novel affinity assessment HYDE(TM) announced to be exclusively marketed by BioSolveIT

Anaheim, CA, USA / St. Augustin, Germany, (PresseBox) - A German scientist consortium just completed a milestone achievement on the way to a very elegant solution to the so-called "Scoring Problem" - the prediction of binding affinity in drug discovery. The new method, HYDE, is said to perform significantly better than those currently available; experts expect a productivity boost for the early phases of the costly drug discovery. Exclusive sales of HYDE are to be conducted by premium software maker BioSolveIT.

Ever since the 80s when the first computer methods emerged, computer predictions of the strength of binding of small molecules in a protein cavity have so far largely failed, even when employing enormously long compute times. Professor Matthias Rarey from the Center for Bioinformatics (ZBH) at the University of Hamburg, consortium member and world renowned expert in the field says: "When we first started this research project almost seven years ago, scientists all over the world were already engaged in the quest for improved scoring functions for more than a decade. It was clear to me that that we had to devise completely new ways to approach this problem. At that time, the key idea for HYDE was introduced to me by Dr. Gudrun Lange and colleagues at Bayer CropScience. Dr. Lange suggested a hitherto unknown, unified description of the most important driving forces to complex formation. This was the basis on which the consortium started to develop HYDE".

BioSolveIT's premium docking suite FlexX, an industry standard for structure-based design, served as the basis of the HYDE implementation. After mastering dozens of seemingly insurmountable hurdles along the way, the development partners ZBH, Bayer CropScience (ISIN DE0005752000 / WKN 575200), and BioSolveIT finally mastered the consistent description of hydrogen bonding, the hydrophobic effect, and desolvation using a single, concise formula.

Early drug discovery applications of HYDE have been reported as being extremely successful. Dr. Lange presented at the ICCS conference in 2008 hit rates of up to 70% in real-life projects. At this year's National ACS Meeting in Anaheim, CA, the successful application of HYDE on several benchmark data sets was reported. FlexX/Hyde ranks among the top-tier computer programs and outperforms the competition on many targets.

"However, more important than any comparison of numbers can ever reveal, HYDE exposes issues with a given lead molecule graphically. It can identify deficiencies and highlights where there is room for improvement. HYDE guides researchers towards new routes for compound optimization by its intuitive, colored visualization: "Green atoms give good scoring contributions, red ones are unfavorable", Dr. Lemmen, CEO of BioSolveIT, explains. "Based on this analysis medicinal chemists will immediately come up with ideas of how to modify a compound for improved binding affinity. We are proud to be part of the team that arrived at what can be considered no less than a breakthrough for predicting binding affinities".

HYDE was released just last Thursday to the general public and presented at the ACS National Meeting in Anaheim, California.

BioSolveIT GmbH

BioSolveIT GmbH ( is a Bio- and Cheminformatics company. Its core businesses are software, services, and research collaborations. With three founders in academia, BioSolveIT has its backbone in science and catalyzes the genesis of products off of basic research successes. The company's software products are world-renowned such as the molecular docking software FlexX and reach a significant customer base. With the FTrees program BioSolveIT took leadership in ultra-fast virtual high throughput screening using a fragment-reassembly based approach. User-friendly GUIs and a suite of fragment based design tools complete BioSolveIT's current software offerings.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.